Mirvetuximab Soravtansine is an experimental medication being studied for its potential to treat certain types of cancer. It is designed to target and bind to specific cancer cells, delivering a toxic substance directly to them to help destroy the cancer cells while minimizing damage to healthy cells. In this trial, it is being tested in combination with another medication to see if it can help prevent the cancer from coming back or getting worse.

Bevacizumab is a medication used to treat various types of cancer. It works by blocking a protein that helps cancer cells grow new blood vessels, which are needed for tumors to grow and spread. By inhibiting this protein, bevacizumab can help slow down or stop the growth of cancer. In this trial, it is used both alone and in combination with another medication to see how effective it is in maintaining the health of patients with certain types of ovarian and related cancers.

Platinum-sensitive epithelial ovarian cancer – This type of cancer originates in the epithelial cells of the ovaries and is characterized by its responsiveness to platinum-based chemotherapy. It often recurs after initial treatment but tends to respond well to subsequent rounds of platinum-based drugs. The disease progresses as cancer cells grow and spread within the ovaries and potentially to other areas of the pelvis and abdomen. Symptoms may include abdominal bloating, pelvic pain, and changes in bowel habits. The progression is typically monitored through imaging and tumor marker tests.

Platinum-sensitive fallopian tube cancer – This cancer arises in the epithelial cells lining the fallopian tubes and shares similarities with ovarian cancer in terms of treatment response. It is termed “platinum-sensitive” because it responds to platinum-based chemotherapy, especially after a period of remission. The disease can spread to nearby organs and tissues, leading to symptoms such as pelvic pain and abnormal vaginal bleeding. Monitoring involves regular imaging and clinical evaluations to assess the extent of disease spread.

Platinum-sensitive primary peritoneal cancer – This cancer develops in the peritoneum, a thin layer of tissue lining the abdomen, and is closely related to ovarian cancer. It is considered platinum-sensitive when it responds to platinum-based chemotherapy after initial treatment. The cancer can spread throughout the abdominal cavity, causing symptoms like abdominal pain and swelling. Disease progression is tracked through imaging studies and clinical assessments to evaluate the response to treatment.